國家衛生研究院 NHRI:Item 3990099045/8602

NHRI > Institute of Biotechnology and Pharmaceutical Research > Ching-Chuan Kuo > Periodical Articles > Item 3990099045/8602

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/8602

Title:	Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo
Authors:	Chen, SJ;Kuo, CC;Pan, HY;Tsou, TC;Yeh, SC;Chang, JY
Contributors:	Institute of Biotechnology and Pharmaceutical Research;National Institute of Cancer Research;Division of Environmental Health and Occupational Medicine
Abstract:	The platinum-based regimen is the front-line treatment of chemotherapy. However, development of platinum resistance often causes therapeutic failure in this disease. We previously have generated an oxaliplatin-resistant subline, named S3, from human cervical carcinoma SiHa cells, and its resistant phenotype was well-characterized. In the present study, we aimed to identify the novel therapeutic strategy by combining copper chelator D-penicillamine with oxaliplatin, and to elucidate the underlying mechanisms for overcoming oxaliplatin resistantce. As the result, D-penicillamine exerted synergistic killing effects only in S3 cells when combined with oxaliplatin and cisplatin by using Chou-Talalay method. Further study showed that the amounts of platinum DNA adduct formed were positively correlated to the percentage of cell death in S3 cells when co-treated D-penicillamine with oxaliplatin and cisplatin. D-penicillamine promoted copper influx transporter hCtr1 expression through upregulation of Sp1. Sp1 overexpression induced p53 translocation from nucleus to cytosol and caused p53 degradation through ubiquitination, which subsequently suppressed the expression of the copper efflux transporter ATP7A. Importantly, co-treatment of cisplatin with D-penicillamine enhanced oxaliplatin-elicited antitumor effect in the oxalipatin-resistant S3 xenograft tumors, but not found in SiHa xenograft model. Notably, Mice received D-penicillamine alone or in combination of D-penicillamine ad oxalipatin, increased hCtrl protein level in S3 xenograft tumor, however, the protein level of ATP7A was decreased. Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, especially in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A.
Date:	2015-05
Relation:	Biochemical Pharmacology. 2015 May;95(1):28-37.
Link to:	http://dx.doi.org/10.1016/j.bcp.2015.03.006
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0006-2952&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000353858800003
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84930883628
Appears in Collections:	[Ching-Chuan Kuo] Periodical Articles [Jang-Yang Chang] Periodical Articles [Tsui-Chun Tsou] Periodical Articles

Files in This Item:

File	Description	Size	Format
SDO0006295215001513.pdf		2796Kb	Adobe PDF	657	View/Open

Loading...